ERBB2 and cancer: The Fab’ fragment of TRZ was selected to target with high‐affinity the HER2‐overexpressing cancer cells, a condition characterizing about 20–30% of invasive breast and ovarian carcinomas.[16] We named this formulation super stealth immunoliposomes (SSIL2).